Work

Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond

Year: 2022

Type: review

Abstract: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant state for a spectrum of lymphoplasmacytic malignancies. The risk of progression of MGUS to a symptomatic therapy requiring plasma cell dyscrasia is about 1% per year. Studies carried out over the previous 10 years have improved risk stratification of MGUS based on serologic and genomic evaluations, which has led to better management of patients. In this review, we address the epidemiology, diagnosis, and pathogenesis of MGUS and discuss risk-adapted best practice approaches to monitor patients.

Source: Faculty Reviews

DOI: 10.12703/r/11-34

Authors: Jithma P Abeykoon, Reema K Tawfiq, Shaji Kumar, Stephen M Ansell

Institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: National Cancer Institute